Nivolumab

• CAT Number: A001234
• CAS Number: 946414-94-4
• Molecular Formula: NA
• Purity: ≥95%
• Synonyms: Nivolumab;BMS 936558;MDX 1106;ONO 4538;Opdivo
• Target: PD-1
• Storage: Room Temperature

Nivolumab(CAS 946414-94-4), marketed as Opdivo, is a medication used to treat cancer. 


It is a humanized IgG4 anti-PD-1 monoclonal antibody, which works as a checkpoint inhibitor, blocking a signal that would have prevented activated T cells from attacking the cancer, thus allowing the immune system to clear the cancer.

Reference

1: Improved survival ends nivolumab trial early. Cancer Discov. 2014
Sep;4(9):979-80. doi: 10.1158/2159-8290.CD-NB2014-104. Epub 2014 Jul 9. PubMed
PMID: 25185170.
2: Deeks ED. Nivolumab: a review of its use in patients with malignant melanoma.
Drugs. 2014 Jul;74(11):1233-9. doi: 10.1007/s40265-014-0234-4. Review. PubMed
PMID: 25022950.
3: O/’Sullivan Coyne G, Madan RA, Gulley JL. Nivolumab: promising survival signal
coupled with limited toxicity raises expectations. J Clin Oncol. 2014 Apr
1;32(10):986-8. doi: 10.1200/JCO.2013.54.5996. Epub 2014 Mar 3. PubMed PMID:
24590655.
4: Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with
interleukin-2 treatment following nivolumab (anti-PD-1) treatment. J Immunother.
2014 Apr;37(3):187-91. doi: 10.1097/CJI.0000000000000024. PubMed PMID: 24598453.
5: Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X,
Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety,
efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or
-naive melanoma. J Clin Oncol. 2013 Dec 1;31(34):4311-8. doi:
10.1200/JCO.2013.51.4802. Epub 2013 Oct 21. PubMed PMID: 24145345; PubMed Central
PMCID: PMC3837092.